+12.5%
FN vs GSK
+31.2%
-18.8%
-47.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.1% | -1.9% | +5.1% | +3.2% |
| 7D | -1.7% | -1.8% | +0.2% | -1.6% |
| 30D | -22.0% | -2.2% | -19.8% | -21.8% |
| 3M | -43.0% | -1.8% | -41.2% | -43.3% |
| 6M | -27.7% | -10.6% | -17.1% | -26.5% |
| YTD | -10.5% | +4.4% | -14.9% | -9.3% |
| 1Y | +12.5% | +30.4% | -17.9% | +9.6% |
| All | +12.5% | +31.2% | -18.8% | +9.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling